A validated stability indicating RP-HPLC method development and validation of for simultaneous estimation of indacaterol and glycopyrrolate in pharmaceutical dosage form

Gajula Vani*, K. Thejomoorthy2, P.Sreenivasa Prasanna3

1 Department of Pharmaceutical analysis, M.L.College of Pharmacy, S. Konda-523101.
2 Head, Department of Pharmaceutical analysis, M.L.College of Pharmacy, S. Konda-523101.
3 Principal, M.L.College of Pharmacy, S.Konda-523101

Received: 21 April 2021 Revised: 11 May 2021 Accepted: 16 May 2021

Abstract

A simple, Accurate, precise method was developed for the simultaneous estimation of the Indacaterol and Glycopyrrolon in the bulk and pharmaceutical dosage form. The chromatogram was run through Std Denali C18 150 x 4.6 mm, 5m. Mobile phase containing Buffer 0.1%OPA: Acetonitrile taken in the ratio 55:45 was pumped through the column at a flow rate of 0.8 ml/min. The buffer used in this method was 0.1% OPA buffer. The temperature was maintained at 30°C. The optimized wavelength selected was 230.0 nm. The retention time of Indacaterol and Glycopyrrolon were found to 2.323min and 3.140 %RSD of the Indacaterol and Glycopyrrolon were %RSD found to be 0.2% and 0.2% respectively. %Recovery was obtained as 99.39% and 99.41% for Indacaterol and Glycopyrrolon respectively. %Recovery was obtained as 99.39% and 99.41% for Indacaterol and Glycopyrrolon respectively. LOD, LOQ values obtained from regression equations of Indacaterol and Glycopyrrolon were 1.08, 3.28, and 0.25, 1.47 respectively. Regression equation of Indacaterol is y = 24501x + 7142.3, y = 26335x + 7822.7of Glycopyrrolon. Retention times were decreased and run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control tests in Industries.

Keywords: Indacaterol, Glycopyrrolon, RP-HPLC.

Introduction

Indacaterol Maleate (IND) is chemically known as 2-[(5,6-Diethyl-2,3-dihydro-1Hinden-2-yl)amino]-1-hydroxyethyl]-8- hydroxyquinolinol-2(1H)-one (Figure 1). IND stimulate adrenergic β2 receptors in the smooth muscle of the airways. IND prevents airway spasms caused by chronic obstructive pulmonary disease (COPD). This drug is indicated for the treatment of COPD. This causes relaxation of the muscle, thereby increasing the diameter of the airways, which becomes constricted in asthma and COPD [1,2,3].

Fig 01: chemical structure of Indacaterol Maleate

Glycopyrrolon bromide (GLY) is a chemically 1, 1 -dimethylpyrrolidin-1-ium-3-yl 2- cyclopentyl-2-hydroxy phenyl acetate bromide (Figure 2). GLY is a synthetic anticholinergic agent with a quaternary ammonium structure. It reduces secretions in the mouth, throat, airways, and stomach before surgery [4,5]. It used along with other medicines to treat peptic ulcers. The combination of Indacaterol Maleate and
Glycopyrronium Bromide mainly used as β2 adrenoreceptor -agonist and anticholinergic agent with a quaternary ammonium structure and widely used in COPD [6].

![Chemical structure of Glycopyrronium bromide](image)

**Fig 02: chemical structure of Glycopyrronium bromide**

The deep literature review revealed that various analytical methods like spectrophotometric, HPLC, HPTLC, stability indicating HPLC, LC-MS and other methods are reported for estimation of IND and GLY individually and in combined with other dosage form and in biological fluids but none of the analytical method is reported for simultaneous estimation of both the drugs in combined pharmaceutical dosage form [7-13]. Therefore, there is a challenge to develop RP-HPLC and UV spectrophotometric method for the simultaneous estimation of Indacaterol maleate and Glycopyrronium bromide. The present study was involved in a research effort aimed at developing and validating a simple, specific, accurate, economical, and precise RP-HPLC and Absorption correction UV spectrophotometric method for the simultaneous estimation of two drugs in pharmaceutical dosage form.

**Experimental work**

**Materials**

Indacaterol and Glycopyrrolate pure drugs (API), Combination Indacaterol and Glycopyrrolate bromide inhaler (Sequadra), Distilled water, Acetonitrile, Phosphate buffer, Methanol, Potassium dihydrogen ortho phosphate buffer, Ortho-phosphoric acid. All theabove chemicals and solvents are from Rankem

**Instruments**

Electronics Balance-Denver, pH meter -BVK enterprises, India, Ultrasonicator-BVK enterprises, WATERS HPLC 2695 SYSTEM equipped with quaternary pumps, Photo Diode Array detector and Auto sampler integrated with Empower 2 Software.UV-VIS spectrophotometer PG Instruments T60 with special bandwidth of 2 mm and 10mm and matched quartz cells integrated with UV win 6 Software was used for measuring absorbances of Indacaterol and Glycopyrrolate solutions.

**Methods**

**Diluent**

Based up on the solubility of the drugs, diluent was selected, Acetonitrile and Water taken in the ratio of 50:50.

**Preparation of Standard stock solutions**

Accurately weighed 55mg of Indacaterol, 25mg of Glycopyrrolate and transferred to 50ml volumetric flask and 3/4th of diluents was added to these flask and sonicated for 10 minutes. Flask were made up with diluents and labeled as Standard stock solution. (1100µg/ml of Indacaterol and 500µg/ml of Glycopyrrolate).

**Preparation of Standard working solutions (100% solution)**

1ml from each stock solution was pipetted out and taken into a 10ml volumetric flask and made up with diluent. (110µg/ml of Indacaterol and 50µg/ml of Glycopyrrolate).

**Preparation of Sample solutions**

The contents of nasal spray delivered by 50 actuations (110&55 mcg each) were collected in 100 ml volumetric flask. Then 20ml acetonitrile was added, sonicated for 25 min and made up to mark to yield 1100 & 500µg/ml. It was centrifuged for 20 min. Then the supernatant was collected and filtered using 0.45 µm filters using (Millipore, Milford, PVDF).

1ml from sample stock solution was pipetted out and taken into a 10ml volumetric flask and made up with diluent. (110µg/ml of Indacaterol and 50µg/ml of Glycopyrrolate).

**Preparation of buffer**

0.1%OPA Buffer

1ml of ortho phosphoric acid was diluted to 1000ml with HPLC grade water.

**Validation [14,15]**

**System suitability parameters**

The system suitability parameters were determined by preparing standard solutions of Indacaterol (110ppm) and Glycopyrrolate (50ppm) and the solutions were injected six times and the parameters like peak tailing, resolution and USP plate count were determined. The % RSD for the area of six standard injections results should not be more than 2%.
Specificity
Checking of the interference in the optimized method. We should not find interfering peaks in blank and placebo at retention times of these drugs in this method. So this method was said to be specific.

Precision
Preparation of Sample solutions
The contents of nasal spray delivered by 50 actuations (110 & 55 mcg each) were collected in 100 ml volumetric flask. Then 20 ml acetonitrile was added, sonicated for 25 min and made up to mark to yield 110 & 500 µg/ml. It was centrifuged for 20 min. Then the supernatant was collected and filtered using 0.45 µm filters using (Millipore, Milford, PVDF). 1 ml from sample stock solution was pipetted out and taken into a 10 ml volumetric flask and made up with diluent. (110 µg/ml of Indacaterol and 50 µg/ml of Glycopyrrolate)

Linearity
Preparation of Standard stock solutions
Accurately weighed 55 mg of Indacaterol, 25 mg of Glycopyrrolate and transferred to 50 ml volumetric flask and 3/4th of diluents was added to these flask and sonicated for 10 minutes. Flask were made up with diluents and labeled as Standard stock solution. (1100 µg/ml of Indacaterol and 500 µg/ml of Glycopyrrolate)

25% Standard solution
0.25 ml each from two standard stock solutions was pipetted out and made up to 10 ml. (27.5 µg/ml of Indacaterol and 12.5 µg/ml of Glycopyrrolate)

50% Standard solution
0.5 ml each from two standard stock solutions was pipetted out and made up to 10 ml. (55 µg/ml of Indacaterol and 25 µg/ml of Glycopyrrolate)

75% Standard solution
0.75 ml each from two standard stock solutions was pipetted out and made up to 10 ml. (82.5 µg/ml of Indacaterol and 37.5 µg/ml of Glycopyrrolate)

100% Standard solution
1.0 ml each from two standard stock solutions was pipetted out and made up to 10 ml. (110 µg/ml of Indacaterol and 50 µg/ml of Glycopyrrolate)

125% Standard solution
1.25 ml each from two standard stock solutions was pipetted out and made up to 10 ml. (137.5 µg/ml of Indacaterol and 62.5 µg/ml of Glycopyrrolate)

150% Standard solution
1.5 ml each from two standard stock solutions was pipetted out and made up to 10 ml (165 µg/ml of Indacaterol and 75 µg/ml of Glycopyrrolate)

Accuracy
Preparation of Standard stock solutions
Accurately weighed 55 mg of Indacaterol, 25 mg of Glycopyrrolate and transferred to 50 ml volumetric flask and 3/4th of diluents was added to these flask and sonicated for 10 minutes. Flask were made up with diluents and labeled as Standard stock solution. (1100 µg/ml of Indacaterol and 500 µg/ml of Glycopyrrolate).

Preparation of 50% Spiked Solution
1 ml of sample stock solution was taken into a 10 ml volumetric flask, to that 1.0 ml from each standard stock solution was pipetted out, and made up to the mark with diluent.

Preparation of 100% Spiked Solution
2 ml of sample stock solution was taken into a 10 ml volumetric flask, to that 1.0 ml from each standard stock solution was pipetted out, and made up to the mark with diluent.

Preparation of 150% Spiked Solution
2.5 ml of sample stock solution was taken into a 10 ml volumetric flask, to that 1.0 ml from each standard stock solution was pipetted out, and made up to the mark with diluent.

Acceptance Criteria
The % Recovery for each level should be between 98.0 to 102

Robustness
Small deliberate changes in method like Flow rate, mobile phase ratio, and temperature are made but there were no recognized change in the result and are within range as per ICH Guide lines. Robustness conditions like Flow minus (0.9 ml/min), Flow plus (1.1 ml/min), mobile phase minus, mobile phase plus, temperature minus (25°C) and temperature plus (35°C) was maintained and samples were injected in duplicate manner. System suitability parameters were not much effected and all the parameters were passed. % RSD was within the limit.

LOD sample Preparation
0.25 ml each from two standard stock solutions was pipetted out and transferred to two separate 10 ml volumetric flasks and made up with diluents. From the above solutions 0.1 ml each of Indacaterol, Glycopyrrolate, solutions respectively were transferred to 10 ml volumetric flasks and made up with the same diluents
LOQ sample Preparation
0.25ml each from two standard stock solutions was pipetted out and transferred to two separate 10ml volumetric flask and made up with diluent. From the above solutions 0.3ml each of Indacaterol, Glycopyrrolate, solutions respectively were transferred to 10ml volumetric flasks and made up with the same diluent.

Degradation studies [16]

Oxidation
To 1 ml of stock solution of Indacaterol and Glycopyrrolate, 1 ml of 20% hydrogen peroxide (H2O2) was added separately. The solutions were kept for 30 min at 60°C. For HPLC study, the resultant solution was diluted to obtain 110µg/ml & 50µg/ml solution and 10 µl were injected into the system and the chromatograms were recorded to assess the stability of sample.

Acid Degradation Studies
To 1 ml of stock solution Indacaterol and Glycopyrrolate, 1 ml of 2N Hydrochloric acid was added and refluxed for 30mins at 60°C. The resultant solution was diluted to obtain 110µg/ml & 50µg/ml solution and 10 µl solutions were injected into the system and the chromatograms were recorded to assess the stability of sample.

Alkali Degradation Studies
To 1 ml of stock solution Indacaterol and Glycopyrrolate, 1 ml of 2N sodium hydroxide was added and refluxed for 30mins at 60°C. The resultant solution was diluted to obtain 110µg/ml & 50µg/ml solution and 10 µl were injected into the system and the chromatograms were recorded to assess the stability of sample.

Dry Heat Degradation Studies
The standard drug solution was placed in oven at 105°C for 1hr to study dry heat degradation. For HPLC study, the resultant solution was diluted to 110µg/ml & 50µg/ml solution and 10µl were injected into the system and the chromatograms were recorded to assess the stability of the sample.

Photo Stability studies
The photochemical stability of the drug was also studied by exposing the 1100µg/ml & 500µg/ml solution to UV Light by keeping the beaker in UV Chamber for 1days or 200 Watt hours/m² in photo stability chamber. For HPLC study, the resultant solution was diluted to obtain 110µg/ml & 50µg/ml solutions and 10µl were injected into the system and the chromatograms were recorded to assess the stability of sample.

Neutral Degradation Studies
Stress testing under neutral conditions was studied by refluxing the drug in water for 1hrs at temperature of 60°C. For HPLC study, the resultant solution was diluted to 110µg/ml & 50µg/ml solution and 10µl were injected into the system and the chromatograms were recorded to assess the stability of the sample.

Results and Discussion
Optimized wavelength selected was 230nm.

Method development
Method development was done by changing various, mobile phase ratios, buffers etc.

Optimized method

Chromatographic conditions
Mobile phase : 55% OPA (0.1%): 45% Acetonitrile
Flow rate : 1ml/min
Column : Agilent C18 (4.6 x 150mm, 5µm)
Detector wave length : 230nm
Column temperature : 30°C
Injection volume : 10µl
Run time : 6 min
Diluent : Water and Acetonitrile in the ratio 50:50

Results
Both peaks have good resolution, tailing factor, theoretical plate count and resolution.

Fig 03: Optimized Chromatogram

Observation
Indacaterol and Glycopyrronium were eluted at 2.323 min and 3.140 min respectively with good resolution. Plate count and tailing factor was very satisfactory, so this method was optimized and to be validated.

System suitability
All the system suitability parameters were within the range and satisfactory as per ICH guidelines.

Table 01: System suitability parameters for Indacaterol and Glycopyrronium

| Sn | Indacaterol | Glycopyrronium |
|----|-------------|---------------|
| 1  | RT          | USP Tail      | RT US Tail USP Resol |
Discussion

Retention times of Indacaterol and Glycopyrronium were 2.336 min and 3.138 min respectively. We did not find interfering peaks in blank and placebo at retention times of these drugs in this method. So this method was said to be specific.

Linearity

Table 02: Linearity table for Indacaterol and Glycopyrronium

| Conc (µg/mL) | Peak area | Conc (µg/mL) | Peak area |
|--------------|-----------|--------------|-----------|
| 0            | 0         | 0            | 0         |
| 27.5         | 715271    | 12.5         | 342706    |
| 55           | 1311494   | 25           | 689039    |
| 82.5         | 2013645   | 37.5         | 962862    |
| 110          | 2690775   | 50           | 1340523   |
| 137.5        | 3402736   | 62.5         | 1646639   |
| 165          | 4040614   | 75           | 1985997   |

Discussion

According to ICH guidelines plate count should be more than 2000, tailing factor should be less than 2 and resolution must be more than 2. All the system suitable parameters were passed and were within the limits.

Validation

Specificity

Retention times of Indacaterol and Glycopyrronium were 2.336 min and 3.138 min respectively. We did not find interfering peaks in blank and placebo at retention times of these drugs in this method. So this method was said to be specific.
Precision
System Precision
Table 03: System precision table of Indacaterol and Glycopyrronium

| S. No | Area of Indacaterol | Area of Glycopyrronium |
|-------|---------------------|------------------------|
| 1.    | 2694165             | 1331679                |
| 2.    | 2675402             | 1326526                |
| 3.    | 2665723             | 1351324                |
| 4.    | 2678464             | 1351240                |
| 5.    | 2703242             | 1340170                |
| 6.    | 2695349             | 1349125                |
| Mean  | 2685391             | 1341677                |
| S.D   | 14348.5             | 10693.7                |
| %RSD  | 0.5                 | 0.8                    |

Discussion
From a single volumetric flask of working standard solution six injections were given and the obtained areas were mentioned above. Average area, standard deviation and % RSD were calculated for two drugs. % RSD obtained as 0.5% and 0.8% respectively for Indacaterol and Glycopyrronium. As the limit of Precision was less than “2” the system precision was passed in this method.

Repeatability
Table 04: Repeatability table of Indacaterol and Glycopyrronium

| S. No | Area of Indacaterol | Area of Glycopyrronium |
|-------|---------------------|------------------------|
| 1.    | 2682197             | 1341905                |
| 2.    | 2678407             | 1339524                |
| 3.    | 2678537             | 1335420                |
| 4.    | 2679682             | 1336952                |
| 5.    | 2666181             | 1339277                |
| 6.    | 2671939             | 133590                 |
| Mean  | 2676760             | 1338111                |
| S.D   | 5948.9              | 2557.0                 |
| %RSD  | 0.3                 | 0.2                    |

Discussion
Multiple sampling from a sample stock solution was done and six working sample solutions of same concentrations were prepared, each injection from each working sample solution was given and obtained areas were mentioned in the above table. Average area, standard deviation and % RSD were calculated for two drugs and obtained as 0.2% and 0.2% respectively for Indacaterol and Glycopyrronium. As the limit of Precision was less than “2” the system precision was passed in this method.

Intermediate precision (Day-Day Precision):
Table 05 Intermediate precision table of Indacaterol and Glycopyrronium

| S. No | Area of Indacaterol | Area of Glycopyrronium |
|-------|---------------------|------------------------|
| 1.    | 2502753             | 1318488                |
| 2.    | 2517263             | 1314818                |
| 3.    | 2503124             | 1316101                |
| 4.    | 2493270             | 1324397                |
| 5.    | 2498013             | 1341534                |
| 6.    | 2502015             | 1317768                |
| Mean  | 2502740             | 1322184                |
| S.D   | 5948.9              | 2557.0                 |
| %RSD  | 0.3                 | 0.2                    |

Discussion
Multiple sampling from a sample stock solution was done and six working sample solutions of same concentrations were prepared, each injection from each working sample solution was given on the next day of the sample preparation and obtained areas were mentioned in the above table. Average area, standard deviation and % RSD were calculated for two drugs and obtained as 0.3% and 0.8% respectively for Indacaterol and Glycopyrronium. As the limit of Precision was less than “2” the system precision was passed in this method.

Accuracy
Table 06: Accuracy table of Indacaterol

| % Level | Amount Spiked (μg/mL) | Amount Recovered (μg/mL) | % Recovery | Mean % Recovery |
|---------|-----------------------|--------------------------|------------|----------------|
| 50%     | 55                    | 54.70                    | 99.45      |                |
| 55      | 54.10                 | 98.36                    |            |                |
| 55      | 54.65                 | 99.37                    |            |                |

Discussion
Multiple sampling from a sample stock solution was done and six working sample solutions of same concentrations were prepared, each injection from each working sample solution was given and obtained areas were mentioned in the above table. Average area, standard deviation and % RSD were calculated for two drugs and obtained as 0.2% and 0.2% respectively for Indacaterol and Glycopyrronium. As the limit of Precision was less than “2” the system precision was passed in this method.
100% | 110 | 110.24 | 100.22 |
| 110 | 109.65 | 99.68 |
| 110 | 109.51 | 99.55 |

150% | 165 | 163.32 | 98.98 |
| 165 | 164.23 | 99.53 |
| 165 | 163.99 | 99.39 |

Table 07: Accuracy table of Glycopyruronium

| % Level | Amount Spiked (μg/mL) | Amount recovered (μg/mL) | % Recovery | Mean % Recovery |
|---------|-----------------------|--------------------------|------------|----------------|
| 50%     | 25                    | 24.88                    | 99.51      |                |
| 25      | 24.81                 | 99.25                    |
| 25      | 24.90                 | 99.60                    |
| 100%    | 50                    | 49.69                    | 99.54      | 99.41%         |
| 50      | 49.76                 | 99.51                    |
| 50      | 49.54                 | 99.08                    |
| 150%    | 75                    | 74.46                    | 99.28      |                |
| 75      | 74.34                 | 99.11                    |
| 75      | 74.96                 | 99.95                    |

Discussion
Three levels of Accuracy samples were prepared by standard addition method. Triplicate injections were given for each level of accuracy and mean %Recovery was obtained as 99.39% and 99.41% for Indacaterol and Glycopyruronium respectively.

Sensitivity
Table 08: Sensitivity table of Indacaterol and Glycopyruronium

| Molecule    | LOD | LOQ |
|-------------|-----|-----|
| Indacaterol | 1.08| 3.28 |
| Glycopyruronium | 0.48| 1.47 |

Robustness
Table 09: Robustness data for Indacaterol and Glycopyruronium

| S.n.o | Condition                  | % RSD of Indacaterol | % RSD of Glycopyruronium |
|-------|----------------------------|----------------------|--------------------------|
| 1     | Flow rate (-) 0.7ml/min    | 0.2                  | 0.2                      |
| 2     | Flow rate                 | 0.4                  | 0.3                      |

Degradation [16]
Degradation Studies
Degradation studies were performed with the formulation and the degraded samples were injected. Assay of the injected samples was calculated and all the samples passed the limits of degradation.

Table 10: Degradation data for Indacaterol and Glycopyruronium

| S. N. O | Degradation Condition | % Drug Degraded | Purity Angle | Purity Threshold |
|---------|-----------------------|-----------------|--------------|-----------------|
| Indacaterol | Acid                  | 7.72            | 1.1 24            | 3.093            | 6.79  0.4 15 |
| Glycopyruronium | Alkali               | 5.10            | 0.2 17            | 0.299            | 4.61  0.8 73 |
|           | Oxidation             | 4.73            | 0.1 07            | 0.303            | 4.34  0.2 52 |
|           | Thermal               | 3.12            | 1.1 20            | 1.488            | 2.81  0.1 77 |
|           | UV                    | 1.72            | 0.6 35            | 1.391            | 2.06  0.1 46 |
|           | Water                 | 1.13            | 0.5 65            | 1.298            | 1.07  0.2 37 |

Discussion
Robustness conditions like Flow minus (0.7ml/min), Flow plus (0.9ml/min), mobile phase minus (50B:50A), mobile phase plus (60B:40A), temperature minus (25°C) and temperature plus(35°C) was maintained and samples were injected in duplicate manner. System suitability parameters were not much affected and all the parameters were passed. %RSD was within the limit.
Discussion
Regarding the pH adjustment in mobile phase for the acid and base degradation studies have movement in retention time of drugs. But due to neutralized acid sample with 2N Base solution and base sample with 2N Acid solution there will be no change in retention time

Conclusion
A simple, Accurate, precise method was developed for the simultaneous estimation of the Indacaterol and Glycopyrronium in injection form. Retention time of Indacaterol and Glycopyrronium were found to 2.323min and 3.140 % RSD of the Indacaterol and Glycopyrronium were % RSD found to be 0.2% and 0.2% respectively. % Recovery was obtained as 99.39% and 99.41% for Indacaterol and Glycopyrronium respectively. LOD, LOQ values obtained from regression equations of Indacaterol and Glycopyrronium were 1.08, 3.28 and 0.25, 1.47 respectively. Regression equation of Indacaterol is y = 24501x + 7142.3, y = 26335x + 7822.7of Glycopyrronium. Retention times were decreased and run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.

Author Contribution
All authors are Contributed Equally.

Funding
No Funding.

Conflict of Intrest
Authors are Declered no Conflict of Intrest.

References
1. O’Neil MJ. The Merck Index an encyclopedia of Chemicals; Drugs and Biologicals. 14th ed. Merck &Co.Inc; 2006. p. 4244.
2. Bhaskar VH., Amirthalingam S. Clinical Pharmacy. 1st ed. Nirav Prakashan publishers; 2013. p. 61.
3. “Glycopyrrolate” March 2016, https://www.drugs.com/cdi/glycopyrrola te.html. Updated On March 2106.
4. http://www.nps.org.au/publications/heal th-professional/nps-radar/2014/april2014. Updated On 1 April 2014.
5. http://www.vectura.com/news/ultibrobreezhaler-qva149-app. Updated on October 2016.
6. Salem YA, Sherbiny DT, Wasseef DR, Ashry SM. Spectroscopic study on Indacaterol maleate: Analytical applications for control of capsules. International J Pharm Sci Res 2015; 6(3): 592-605.
7. Salem YA, Sherbiny DT, Wasseef DR, Ashry SM. HPLC Determination of Indacaterol Maleate in Pharmaceutical Preparations Adopting Ultraviolet and Fluorescence Detection. International J Pharm Sci Res 2015; 6(2): 1324-1332.
8. Wesam GA, Al-Qadhi Z, Mohammad K, Rabab T, Qammaz S, Orijuat G, Basheti IA, Chrystyn H. A Validated Liquid Chromatography-Tandem Mass Spectrometry Coupled with LiquidLiquid Extraction for Indacaterol Quantitation in Human Plasma. Advance Pharmacol Pharm 2015; 3(2): 43-51.
9. Gandala K, Pabba P, Akula G. RP-HPLC method development and validation for estimation of glycopyrrolate in bulk and tablet dosage forms Asian J Pharm Clin Res 2011; 4(4): 37-40.
10. Venketshwaran TG, King DT, Stewart JT. HPLC determination of oldansetronatropine and oldansetron-glycopyrrolate mixtures in 0.9% sodium chloride injection.Journalliquichrom 2006; 18(13): 2647-2659.
11. United State Pharmacopoeia USP30, NF 25, US Pharmacopoeial Convention INC.; Rockville; 2007. p. 2242-2742.
12. British Pharmacopoeia, Vol 2 & 3. Her Majesty’s Stationary Office: London; 2013. p. 334.
13. ICH, Q2 (R1), Harmonized tripartite guideline, Validation of analytical procedures: text and methodology, International Conference on Harmonization ICH, Geneva, Nov 2005.
14. Rao CP, Rahaman SA, Prasad YR, Reddy PG. RP-HPLC method of simultaneous estimation of amlodipine besylate and metoprolol in combined dosage form. International Journal of Pharmaceutical Research and Development. 2010 Nov;2(9):69-76.
15. Rao CM, Konda R, Ramanjeneeyulu S. Estimation of Nevirapine Anhydrous Bulk Formulation by Using IR, RP-HPLC, GC Methods. Research Journal of Pharmacy and Technology. 2010 Dec 28;3(4):1088-92.
16. Ch M M Prasada et al, Development and Validation of a Novel Stability Indicating RP-
17. Lavina Rajawat, Jigna T Patel, Chirag J Patel, and M. M. Patel. “RP-HPLC Method Development And Validation Of Tetrabenazine With Its Known And Unknown Degra-Dation Impurities In Its Tablet Dosage Form”. *International Journal of Pharmaceutics and Drug Analysis*, Apr. 2018, pp. 453-6.

18. Rowthula Prasanna Surya Bhavani, R. P. S. B., and M. M. M. Sandhya Maduri. “stability indicating method development and validation for the simultaneous estimation of ledipasvir and sofosbuvir in bulk drug by using rp-hplc”. *World Journal of Current Medical and Pharmaceutical Research*, Nov. 2020, pp. 307-18, doi:10.37022/wjcmpr.vi.159.